GlassScriptPhysician profile
Tanveer A Malik
NPI 1336129840
$3,958.91
in general payments reported to CMS, 2019-2025
31 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $60.18 · 2021: $291 · 2022: $469 · 2023: $464 · 2024: $562 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $870.23 | 2019-2025 | Jot Dx |
| Novartis Pharmaceuticals Corporation | $571.30 | 2020-2025 | |
| Amgen INC. | $350.35 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $243.52 | 2021-2025 | |
| Boston Scientific Corporation | $228.85 | 2023-2025 | Watchman Access System, Bodyguardian, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $226.97 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $195.85 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $189.78 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $148.32 | 2022-2025 | |
| Novo Nordisk INC | $121.25 | 2025 | Wegovy, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $118.88 | 2022-2025 | Eliquis, Camzyos |
| Actelion Pharmaceuticals US, INC. | $88.56 | 2024 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.50 | 2025 | Jardiance |
| Sensible Medical Innovations INC | $78.21 | 2022 | |
| Philips North America LLC | $54.81 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.14 | 2022-2023 | |
| Bridgebio Pharma, INC. | $45.58 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $38.99 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $28.62 | 2024 | Zio Monitor, Zio Xt Patch |
| Alnylam Pharmaceuticals INC. | $24.91 | 2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $24.44 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $22.79 | 2019 | |
| Heartflow, INC. | $19.54 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $19.08 | 2023 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $18.82 | 2025 | Edarbyclor |
| Esperion Therapeutics, INC. | $18.48 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.86 | 2021 | |
| Lilly USA, LLC | $16.87 | 2025 | Mounjaro, Zepbound |
| Baxter Healthcare | $15.46 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Stryker Corporation | $15.01 | 2021 | |
| Braemar Manufacturing, LLC | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanveer Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.